BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HC Biopharma Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies HC Biopharma Inc.'s drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07169552-2129@assetmemo.bio
DTSTAMP:20261121T005935Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HC010: Phase 2 readout est. (NCT07169552)
DESCRIPTION:HC010\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: HC010 in 
 First-line PD-L1 Positive Advanced NSCLC Patients\nEstimated primary compl
 etion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/hc010#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07169552
URL:https://assetmemo.bio/drug/hc010#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
